Loading quotes...

Forecast

The analysts' average price target is €1,009.85 (+29.47%). The median is €997.98 (+27.95%).

Buy	32
Hold	4
Sell	0

News Go to news feed

arGEN-X achieves strong revenue growth with Vyvgart, misses operating profit expectations

In the third quarter, group revenue at arGEN-X rose to $1.72 billion thanks to the drug Vyvgart, but operating income of $486 million was below analysts' expectations of $551 million. Net income attributable to shareholders amounted to $506 million; the result was weighed down in part by higher research and marketing costs. The company announced a label expansion for Vyvgart Hytrulo and another regulatory‑relevant study for dermatomyositis. » More on finanzen.net
arGEN-X grows strongly thanks to Vyvgart, but misses profit expectations

In the third quarter arGEN-X's revenue rose by more than half to $1.72 billion, almost entirely driven by the drug Vyvgart. Operating income climbed 40% to $486 million, but fell short of analysts' expectation of around $551 million. Higher research and marketing costs weighed on profitability; net income attributable to shareholders was $506 million (previous year $344 million). The stock fell in Brussels by up to about 2.6%. » More on finanzen.net
arGEN-X halts phase-III study of Efgartigimod Sc after negative interim analysis

arGEN-X has discontinued the advanced phase-III study of Efgartigimod Sc for the treatment of Sjögren’s syndrome after an interim analysis showed the main study endpoint could not be reached. The share price fell sharply at times, dropping about 9 percent in Tradegate trading to roughly €750. The company currently generates almost all of its revenue from Efgartigimod Alfa for myasthenia gravis and is seeking additional growth sources. At the same time, arGEN-X reported positive phase-II results for candidate FB102 in celiac disease and plans to move it into phase III. » More on finanzen.net

Financials

In the last quarter, arGEN-X had revenue of €2.47bn and net profit of €734.99m

(EUR)	June 2026	YoY
Revenue	2.47bn	-
Gross profit	2.22bn	-
Net profit	734.99m	-
EBITDA	756.91m	-

Fundamentals

Metric	Value
Market capitalization	€48.96bn
Number of shares	62.89m
52-week high/low	€955.87 - €589.74
Dividends	No
Beta	-0.02
P/E ratio	31.76
PEG ratio	0.09
P/B ratio	6.47
P/S ratio	10.62

Company profile

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.